Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro

Cioccoloni,Giorgia; Bonmassar,Laura; Pagani,Elena; Caporali,Simona; Fuggetta,Maria  Pia; Bonmassar,Enzo; D'Atri,Stefania; Aquino,Angelo

doi:10.3892/ijo.2015.3025

Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro

Authors:
- Giorgia Cioccoloni
- Laura Bonmassar
- Elena Pagani
- Simona Caporali
- Maria Pia Fuggetta
- Enzo Bonmassar
- Stefania D'Atri
- Angelo Aquino
View Affiliations

Affiliations: Department of Systems Medicine, University of Rome ‘Tor Vergata’, I-00133 Rome, Italy, Laboratory of Molecular Oncology, Istituto Dermopatico dell'Immacolata-IRCCS, I-00167 Rome, Italy, Institute of Translational Pharmacology (IFT), National Research Council (CNR), I-00133 Rome, Italy
Published online on: May 29, 2015 https://doi.org/10.3892/ijo.2015.3025
Pages: 764-772

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tetrahydrolipstatin (orlistat), an inhibitor of lipases and fatty acid synthase, is used orally for long-term treatment of obesity. Although the drug possesses striking antitumor activities in vitro against human cancer cells and in vitro and in vivo against animal tumors, it also induces precancerous lesions in rat colon. Therefore, we tested the in vitro effect of orlistat on the expression of O6-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme that plays an essential role in the control of mutagenesis and carcinogenesis. Western blot analysis demonstrated that 2-day continuous exposure to 40 µM orlistat did not affect MGMT levels in a human melanoma cell line, but downregulated the repair protein by 30-70% in human peripheral blood mononuclear cells, in two leukemia and two colon cancer cell lines. On the other hand, orlistat did not alter noticeably MGMT mRNA expression. Differently from lomeguatrib (a false substrate, strong inhibitor of MGMT) orlistat did not reduce substantially MGMT function after 2-h exposure of target cells to the agent, suggesting that this drug is not a competitive inhibitor of the repair protein. Combined treatment with orlistat and lomeguatrib showed additive reduction of MGMT levels. More importantly, orlistat-mediated downregulation of MGMT protein expression was markedly amplified when the drug was combined with a DNA methylating agent endowed with carcinogenic properties such as temozolomide. In conclusion, even if orlistat is scarcely absorbed by oral route, it is possible that this drug could reduce local MGMT-mediated protection against DNA damage provoked by DNA methylating compounds on gastrointestinal tract epithelial cells, thus favoring chemical carcinogenesis.

View Figures

View References

1	Yanovski SZ and Yanovski JA: Long-term drug treatment for obesity: A systematic and clinical review. JAMA. 311:74–86. 2014. View Article : Google Scholar :
2	Flavin R, Peluso S, Nguyen PL and Loda M: Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6:551–562. 2010. View Article : Google Scholar : PubMed/NCBI
3	Santolla MF, Lappano R, De Marco P, Pupo M, Vivacqua A, Sisci D, Abonante S, Iacopetta D, Cappello AR, Dolce V, et al: G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts. J Biol Chem. 287:43234–43245. 2012. View Article : Google Scholar : PubMed/NCBI
4	Chuang HY, Chang YF and Hwang JJ: Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother. 65:286–292. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rossato FA, Zecchin KG, La Guardia PG, Ortega RM, Alberici LC, Costa RA, Catharino RR, Graner E, Castilho RF and Vercesi AE: Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melana cells associated with inhibition of mitochondrial respiration. PLoS One. 9:e1010602014. View Article : Google Scholar
6	Little JL, Wheeler FB, Fels DR, Koumenis C and Kridel SJ: Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 67:1262–1269. 2007. View Article : Google Scholar : PubMed/NCBI
7	Zeng L, Wu GZ, Goh KJ, Lee YM, Ng CC, You AB, Wang J, Jia D, Hao A, Yu Q, et al: Saturated fatty acids modulate cell response to DNA damage: Implication for their role in tumorigenesis. PLoS One. 3:e23292008. View Article : Google Scholar : PubMed/NCBI
8	Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, Vöhringer MC, Horn H, Ott G, Aulitzky WE and van der Kuip H: Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: A potential Achilles’ heel in mantle cell lymphoma. Cell Death Dis. 5:e10132014. View Article : Google Scholar
9	Garcia SB, Barros LT, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, Vespúcio MV and Uyemura SA: The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 240:221–224. 2006. View Article : Google Scholar
10	Nairooz S, Ibrahim SH, Sahar MMO and Affan M: Structural changes of the colonic mucosa induced by Orlistat: Experimental study. Egypt J Histol. 33:635–648. 2010.
11	Christmann M, Verbeek B, Roos WP and Kaina B: O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta. 1816:179–190. 2011.PubMed/NCBI
12	Fahrer J and Kaina B: O⁶-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer. Carcinogenesis. 34:2435–2442. 2013. View Article : Google Scholar : PubMed/NCBI
13	Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS and Ogino S: PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia. 10:534–541. 2008. View Article : Google Scholar : PubMed/NCBI
14	Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, Jiricny J and D’Atri S: The effect of O⁶-alkyl-guanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther. 304:661–668. 2003. View Article : Google Scholar : PubMed/NCBI
15	Watson AJ and Margison GP: O(6)-Alkylguanine-DNA alkyl-transferase assay. Methods Mol Med. 28:167–178. 1999.
16	Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, et al: Lomeguatrib, a potent inhibitor of O⁶-alkylguanine-DNA-alkyltransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 12:1577–1584. 2006. View Article : Google Scholar : PubMed/NCBI
17	Srivenugopal KS, Yuan XH, Friedman HS and Ali-Osman F: Ubiquitination-dependent proteolysis of O⁶-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O⁶-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry. 35:1328–1334. 1996. View Article : Google Scholar : PubMed/NCBI
18	Turriziani M, Caporaso P, Bonmassar L, Buccisano F, Amadori S, Venditti A, Cantonetti M, D’Atri S and Bonmassar E: O⁶-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O⁶-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res. 53:317–323. 2006. View Article : Google Scholar : PubMed/NCBI
19	Pegg AE and Byers TL: Repair of DNA containing O⁶-alkyl-guanine. FASEB J. 6:2302–2310. 1992.PubMed/NCBI
20	Kyrtopoulos SA, Anderson LM, Chhabra SK, Souliotis VL, Pletsa V, Valavanis C and Georgiadis P: DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. Cancer Detect Prev. 21:391–405. 1997.PubMed/NCBI
21	Gouws C and Pretorius PJ: O⁶-methylguanine-DNA methyltransferase (MGMT): Can function explain a suicidal mechanism? Med Hypotheses. 77:857–860. 2011. View Article : Google Scholar : PubMed/NCBI
22	Wojciechowicz K, Cantelli E, Van Gerwen B, Plug M, Van Der Wal A, Delzenne-Goette E, Song JY, De Vries S, Dekker M and Te Riele H: Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome. Gastroenterology. 147:1064–1072.e5. 2014. View Article : Google Scholar : PubMed/NCBI
23	D’Atri S, Graziani G, Lacal PM, Nisticò V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E and Margison GP: Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther. 294:664–671. 2000.
24	Xiao W and Samson L: In vivo evidence for endogenous DNA alkylation damage as a source of spontaneous mutation in eukaryotic cells. Proc Natl Acad Sci USA. 90:2117–2121. 1993. View Article : Google Scholar : PubMed/NCBI
25	Iyama T and Wilson DM III: DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst). 12:620–636. 2013. View Article : Google Scholar
26	Ito T, Nakamura T, Maki H and Sekiguchi M: Roles of transcription and repair in alkylation mutagenesis. Mutat Res. 314:273–285. 1994. View Article : Google Scholar : PubMed/NCBI
27	Bak ST, Sakellariou D and Pena-Diaz J: The dual nature of mismatch repair as antimutator and mutator: For better or for worse. Front Genet. 5:2872014. View Article : Google Scholar : PubMed/NCBI
28	Cohen SA and Leininger A: The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. Appl Clin Genet. 7:147–158. 2014. View Article : Google Scholar : PubMed/NCBI
29	Aquilina G, Biondo R, Dogliotti E, Meuth M and Bignami M: Expression of the endogenous O⁶-methylguanine-DNA-methyltransferase protects Chinese hamster ovary cells from spontaneous G:C to A:T transitions. Cancer Res. 52:6471–6475. 1992.PubMed/NCBI
30	Paranjpe A, Zhang R, Ali-Osman F, Bobustuc GC and Srivenugopal KS: Disulfiram is a direct and potent inhibitor of human O⁶-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis. 35:692–702. 2014. View Article : Google Scholar :
31	Xu-Welliver M and Pegg AE: Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis. 23:823–830. 2002. View Article : Google Scholar : PubMed/NCBI
32	Khan O and Middleton MR: The therapeutic potential of O⁶-alkylguanine DNA alkyltransferase inhibitors. Expert Opin Investig Drugs. 16:1573–1584. 2007. View Article : Google Scholar : PubMed/NCBI
33	Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F and De Vecchis L: Triazene compounds: Mechanism of action and related DNA repair systems. Pharmacol Res. 56:275–287. 2007. View Article : Google Scholar : PubMed/NCBI
34	Bonmassar L, Marchesi F, Pascale E, Franzese O, Margison GP, Bianchi A, D’Atri S, Bernardini S, Lattuada D, Bonmassar E, et al: Triazene compounds in the treatment of acute myeloid leukemia: A short review and a case report. Curr Med Chem. 20:2389–2401. 2013. View Article : Google Scholar : PubMed/NCBI
35	Seiter K, Katragadda S, Ponce D, Rasul M and Ahmed N: Temozolomide and cisplatin in relapsed/refractory acute leukemia. J Hematol Oncol. 2:212009. View Article : Google Scholar : PubMed/NCBI
36	Zhang J, Stevens MF and Bradshaw TD: Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol. 5:102–114. 2012. View Article : Google Scholar
37	Niture SK, Velu CS, Smith QR, Bhat GJ and Srivenugopal KS: Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. Carcinogenesis. 28:378–389. 2007. View Article : Google Scholar
38	Liu L, Allay E, Dumenco LL and Gerson SL: Rapid repair of O⁶-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res. 54:4648–4652. 1994.PubMed/NCBI
39	Nakatsuru Y, Matsukuma S, Nemoto N, Sugano H, Sekiguchi M and Ishikawa T: O⁶-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc Natl Acad Sci USA. 90:6468–6472. 1993. View Article : Google Scholar
40	Griesenbeck JS, Steck MD, Huber JC Jr, Sharkey JR, Rene AA and Brender JD: Development of estimates of dietary nitrates, nitrites, and nitrosamines for use with the Short Willet Food Frequency Questionnaire. Nutr J. 8:162009. View Article : Google Scholar : PubMed/NCBI
41	Orsolin PC, Silva-Oliveira RG and Nepomuceno JC: Assessment of the mutagenic, recombinagenic and carcinogenic potential of orlistat in somatic cells of Drosophila melanogaster. Food Chem Toxicol. 50:2598–2604. 2012. View Article : Google Scholar : PubMed/NCBI
42	Kridel SJ, Axelrod F, Rozenkrantz N and Smith JW: Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 64:2070–2075. 2004. View Article : Google Scholar : PubMed/NCBI
43	Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF and Pizer ES: Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 61:1493–1499. 2001.PubMed/NCBI
44	Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HC, Castilho RF, Coletta RD, Vercesi AE and Graner E: Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Invest. 91:232–240. 2011. View Article : Google Scholar
45	Kant S, Kumar A and Singh SM: Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: Implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta. 1840:294–302. 2014. View Article : Google Scholar
46	Bocangel D, Sengupta S, Mitra S and Bhakat KK: p53-mediated downregulation of the human DNA repair gene O⁶-methyl-guanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 29:3741–3750. 2009.PubMed/NCBI